Study: NCT01111851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant 150 mg
Description: a single intravenous infusion of 150 mg fosaprepitant dimeglumine over 20 minutes on Day 1 15 minutes after consumption of a standard light breakfast meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 165 mg
Description: a single oral 165 mg aprepitant capsule 15 minutes after consumption of a standard light breakfast meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 250 mg
Description: a single oral 250 mg dose achieved by administering two 125 mg aprepitant capsules 15 minutes after consumption of a standard light breakfast meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (12-8-16-16 mg)
Description: Dexamethasone 12 mg will be administered orally 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg twice daily), and Day 4 (8 mg twice daily) with or without a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (12-8-16-16 mg)
Description: Dexamethasone 12 mg will be administered orally 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg twice daily), and Day 4 (8 mg twice daily) with or without a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (12-8-8-16 mg)
Description: Dexamethasone 12 mg will be administered orally 30 minutes after after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg), and Day 4 (8 mg twice daily) with or without a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: The intravenous (I.V.) infusion of ondansetron 32 mg will begin 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1 and will be administered as a 15-minute infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: The intravenous (I.V.) infusion of ondansetron 32 mg will begin 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1 and will be administered as a 15-minute infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: The intravenous (I.V.) infusion of ondansetron 32 mg will begin 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1 and will be administered as a 15-minute infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0999
Description: I.V. infusion of MK0999 containing \~100 MBq (\~3 mCi) containing ≤ 5 ug of MK0999)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0999
Description: I.V. infusion of MK0999 containing \~100 MBq (\~3 mCi) containing ≤ 5 ug of MK0999)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0999
Description: I.V. infusion of MK0999 containing \~100 MBq (\~3 mCi) containing ≤ 5 ug of MK0999)